Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | UBE2M | P61081 | 1/20 | 0.41 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.41 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.41 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5062062 | 0.87 | ALDH1A1 (0.48) | PPARGTP53UBE2MDCUN1D1LMNA | |
| SCHEMBL27679675 | 0.83 | LMNA (0.50) | CNR1LMNAALOX15TSHRMAPK1 | |
| SCHEMBL5287621 | 0.81 | TACR1 (0.54) | LMNA | |
| SCHEMBL1228585 | 0.79 | FAAH (0.42) | TP53UBE2MDCUN1D1PTGER2LMNA | |
| SCHEMBL1043735 | 0.78 | MEN1 (0.54) | TP53GAALMNA | |
| SCHEMBL13162592 | 0.78 | EPHX2 (0.39) | PPARGLMNAMAPK1CASP8 | |
| SCHEMBL9109184 | 0.78 | SPR (0.44) | — | |
| SCHEMBL5057785 | 0.77 | CNR1 (0.36) | CNR1PPARGTP53GAA | |
| SCHEMBL2952296 | 0.76 | CASP8 (0.42) | TSHRCASP8 | |
| SCHEMBL5061924 | 0.76 | ALDH1A1 (0.45) | PPARGTP53LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306114-A1 | Human G Protein-Coupled Receptor and Modulators Thereof for the Treatment of Hyperglycemia and Related Disorders | ARENA PHARMACEUTICALS, INC (US) | 2008-12-11 | — | — | US | disclosed |
| US-20070231263-A1 | Human G protein-coupled receptor and modulators thereof for the treatment of hyperglycemia and related disorders | ARENA PHARMACEUTICALS, INC. | 2007-10-04 | — | — | US | disclosed |
| EP-1735622-A2 | MODULATORS OF HUMAN G PROTEIN-COUPLED RECEPTORS FOR THE TREATMENT OF HYPERGLYCEMIA AND RELATED DISORDERS | Arena Pharmaceuticals, Inc. (US) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005116653-A2 | MODULATORS OF HUMAN G PROTEIN-COUPLED RECEPTORS FOR THE TREATMENT OF HYPERGLYCEMIA AND RELATED DISORDERS | ARENA PHARMACEUTICALS, INC. (US) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070231263-A1 | Human G protein-coupled receptor and modulators thereof for the treatment of hyperglycemia and related disorders | GPR119, GCGR, GLP1R | CNR1 90/4885PPARG 101/4885TP53 4042/4885 |
| US-20080306114-A1 | Human G Protein-Coupled Receptor and Modulators Thereof for the Treatment of Hyperglycemia and Related Disorders | GPR119, GCGR, GLP1R | CNR1 90/4885PPARG 101/4885TP53 4042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.